据媒体报道，2月20日上午，省新型冠状病毒肺炎疫情防控工作领导小组办公室举行的防疫发展“两手抓”复工复产“四带头”新闻发布会上， 智 科马生物制药有限公司总经理蒲江介绍，目前疫苗正处于临床前研究阶段，预计6月份可以进入临床试验。
Novel coronavirus pneumonia prevention and control work leading group office in Anhui province held the "four leading" resumption of production and "resumption of production" in the forenoon of February 20th. According to media reports, Pujiang, the general manager of Anhui Zhi Fei Long Ma Biological Pharmaceutical Co., Ltd., is currently in pre clinical research stage, and is expected to enter clinical trials in June.
据了解，目前国内外科研机构分别采用灭活疫苗、亚疫苗、病毒载体疫苗、核酸疫苗等不同技术路径开发新型冠状病毒疫苗，而智 科马研发的亚 疫苗则具有众多优势：
It is understood that novel coronavirus vaccines are developed by different domestic and foreign scientific research institutions, including inactivated vaccine, subunit vaccine, viral vector vaccine, nucleic acid vaccine and so on.
(1) Without nucleic acid, it has higher security and better stability;
(2) With strong immunogenicity and lasting immunity, it can not only produce humoral immune response, but also induce cellular immunity;
(3) With the help of engineering cell expression system, large-scale production can be realized quickly.
Since the Spring Festival holiday, the R & D personnel of zhifeilongcoma have been working overtime. At present, the new crown vaccine they developed has completed the design of vaccine antigen sequence and the construction of expression vector. They are carrying out the work of engineering cell line screening. At the same time, they have prepared a batch of antigen proteins and are carrying out the validation of vaccine effectiveness.
Pujiang said that according to the current progress, the company's new library virus vaccine is expected to apply for clinical trials in June this year. "The new coronavirus vaccine is an innovative vaccine, and the risk of the vaccine should be fully evaluated. We will spare no effort to overcome difficulties and strive to get the vaccine approved for market as soon as possible on the premise of ensuring the safety and effectiveness of the vaccine. "
Disclaimer: This article is reproduced for the purpose of transmitting more information. If there is a source marking error or infringing your legitimate rights and interests, please contact our website with the ownership certificate. We will correct and delete it in time. Thank you.